Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Nephrolithiasis in renal tubular acidosis

As a subscriber you will have access to the full contents of this article

INTRODUCTION

Hypercalciuria, hypocitraturia, nephrolithiasis (often composed of calcium phosphate), nephrocalcinosis, and skeletal abnormalities are frequently associated with untreated type 1 renal tubular acidosis (RTA) [1-4]. Stone disease is also seen with carbonic anhydrase inhibitors but typically not with type 2 RTA. Most of the studies on RTA and nephrolithiasis were quite small, and there is variability in individual phenotype and the response to therapy. As a result, the following statements should be read with these cautions in mind.

PATHOGENESIS

Type 1 RTA — Several factors can contribute to the relationship between type 1 RTA and stone formation or nephrocalcinosis. In some families, for example, hypercalciuria appears to be the primary abnormality, with calcium-induced interstitial and tubular damage possibly responsible for the RTA [2].

In most cases, however, RTA is the initial condition with subsequent acidemia, promoting stone formation both by increased calcium phosphate release from bone during bone buffering of retained acid and by direct reduction of the tubular reabsorption of these ions [1,5,6]. The degree of hypercalciuria is roughly proportional to the severity of the acidemia.

Two other factors also contribute importantly to stone formation in this disorder: the persistently high urine pH, which favors the precipitation of calcium phosphate (but not calcium oxalate, the solubility of which is relatively insensitive to pH); and reduction citrate excretion [7], since acidemia enhances proximal citrate reabsorption [8]. Citrate is normally a potent inhibitor of stone formation, both by forming a soluble complex with calcium and by inhibiting stone growth by agglomeration of calcium crystals. (See "Risk factors for calcium stones in adults".)

Kidney histopathology of stone formers with type 1 RTA reveals calcium phosphate deposits plugging inner medullary collecting and Bellini ducts [9]. Significant interstitial fibrosis is also observed, even in areas without plugging. Although further study is needed to verify these results, the findings suggest that some of the radiographic calcifications in these patients may represent surgically approachable stones rather than nephrocalcinosis.

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2009 UpToDate, Inc.
References Top
  1. Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. pp. 616-618.
  2. Buckalew, VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol 1989; 141(3 Pt 2):731.
  3. Brenner, RJ, Spring, DB, Sebastian, A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.
  4. Gault, MH, Chafe, LL, Morgan, JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.
  5. Bleich, HL, Moore, MJ, Lemann, J Jr, et al. Urinary calcium excretion in human beings. N Engl J Med 1979; 301:535.
  6. Nijenhuis, T, Renkema, KY, Hoenderop, JG, Bindels, RJ. Acid-base status determines the renal expression of Ca2+ and Mg2+ transport proteins. J Am Soc Nephrol 2006; 17:617.
  7. Norman, ME, Feldman, NI, Cohn, RM, et al. Urinary citrate excretion in the diagnosis of distal renal tubular acidosis. J Pediatr 1978; 92:394.
  8. Hamm, LL. Renal handling of citrate. Kidney Int 1990; 38:728.
  9. Evan, AP, Lingeman, J, Coe, F, et al. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007; 71:795.
  10. Tawil, R, Moxley, RT 3rd, Griggs, RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43:1105.
  11. Ahlstrand, C, Tiselius, HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21:225.
  12. Kuo, RL, Moran, ME, Kim, DH, et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16:229.
  13. Leppik, IE, Willmore, LJ, Homan, RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14:165.
  14. Kubota, M, Nishi-Nagase, M, Sakakihara, Y, et al. Zonisamide - induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000; 22:230.
  15. Sheth, RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004; 63:S24.
  16. Welch, BJ, Graybeal, D, Moe, OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48:555.
  17. LaRoche, SM, Helmers, SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291:605.
  18. Preminger, GM, Sakhaee, K, Skurla, C, Pak, CYC. Prevention of renal calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134:20.
  19. Sakhaee, K, Nicar, M, Hill, K, Pak, CYC. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24:348.
  20. Lemann, J Jr, Gray, RW, Pleuss, JA. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int 1989; 35:688.
  21. Coe, FL, Parks, JH, Asplin, JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.
white circle LOG IN
white circle DEMO